David Z I Cherney (David Cherney, David Z Cherney)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 49

Top Topics

Editorial Comment

Acute Heart Failure

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

Canadian journal of kidney health and disease

This page only lists publications with an associated author ORCID identifier.

Publications

Joseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack, David Z I Cherney, Francesco Cosentino, Darren K McGuire, Richard E Pratley, Chih-Chin Liu, Nilo B Cater, Robert C Frederich, James P Mancuso, Christopher P Cannon
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease. Diabetes, obesity & metabolism (2023)
David Z I Cherney, Alan Bell, Louis Girard, Philip McFarlane, Louise Moist, Sharon J Nessim, Steven Soroka, Sara Stafford, Andrew Steele, Navdeep Tangri, Jordan Weinstein
Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. Canadian journal of kidney health and disease 10 (2023)
Hiddo J Lambers Heerspink, Ellen Apperloo, Melanie Davies, Dror Dicker, Kristian Kandler, Julio Rosenstock, Rasmus Sørrig, Jack Lawson, Niels Zeuthen, David Z I Cherney
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials. Diabetes care (2023)
Ambarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, Christopher P Cannon, Robert C Frederich, David Z I Cherney, Samuel Dagogo-Jack, Richard E Pratley, Nilo B Cater, Ira Gantz, James P Mancuso, Darren K McGuire
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. European heart journal (2023)
Joseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack, David Z I Cherney, Francesco Cosentino, Darren K McGuire, Richard E Pratley, Chih-Chin Liu, Nilo B Cater, Robert Frederich, James P Mancuso, Christopher P Cannon
Potential for Residual Cardiovascular Risk Reduction: Eligibility for Icosapent Ethyl in the VERTIS CV Population with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Diabetes, obesity & metabolism (2023)
Vikas S Sridhar, Hiddo J Lambers Heerspink, Michael J Davies, Phillip Banks, Manon Girard, Satish K Garg, David Z I Cherney
The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3. Diabetes care (2023)
Hiddo J Lambers Heerspink, Naveed Sattar, Imre Pavo, Axel Haupt, Kevin L Duffin, Zhengyu Yang, Russell J Wiese, Jonathan M Wilson, Andrea Hemmingway, David Z I Cherney, Katherine R Tuttle
Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis. Diabetes care (2023)
David Z I Cherney, Eleuterio Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, David R Powell, Michael J Davies, Phillip Banks, Rajiv Agarwal
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diabetes, obesity & metabolism (2023)
David Z I Cherney, Alan Bell, Louis Girard, Philip McFarlane, Louise Moist, Sharon J Nessim, Steven Soroka, Sara Stafford, Andrew Steele, Navdeep Tangri, Jordan Weinstein
Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. Canadian journal of kidney health and disease 10 (2023)
Vikas S Sridhar, Brendon L Neuen, Robert A Fletcher, April Slee, Fernando G Ang, Wally Rapattoni, Clare Arnott, David Z I Cherney, Vlado Perkovic, David C Wheeler, Adeera Levin
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials. Diabetes, obesity & metabolism (2023)
David Z I Cherney, Dick de Zeeuw, Hiddo J Lambers Heerspink, Jose Cardona, Marc Desch, Arne Wenz, Friedrich Schulze, Masaomi Nangaku
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial. Diabetes, obesity & metabolism (2023)
David Z I Cherney, Eleuterio Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, David R Powell, Michael J Davies, Phillip Banks, Rajiv Agarwal
Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes and Stage 3 Chronic Kidney Disease. Diabetes, obesity & metabolism (2023)
David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong, Christopher P Cannon, null null
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. Diabetologia 65 (5) (2022)
Brendon L Neuen, Megumi Oshima, Rajiv Agarwal, Clare Arnott, David Z I Cherney, Robert Edwards, Anna Maria Langkilde, Kenneth W Mahaffey, Darren K McGuire, Bruce C Neal, Vlado Perkovic, Annpey Pong, Marc S Sabatine, Itamar Raz, Tadashi Toyama, Christoph Wanner, David C Wheeler, Stephen D Wiviott, Bernard Zinman, Hiddo J Lambers Heerspink
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation 145 (19) (2022)
Matthew W Segar, Ahmed A Kolkailah, Robert Frederich, Annpey Pong, Christopher P Cannon, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard E Pratley, Chih-Chin Liu, Mario Maldonado, Jie Liu, Nilo B Cater, Ambarish Pandey, David Z I Cherney
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism 24 (9) (2022)
Karen D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, Francesco Cosentino, Robert Frederich, Jie Liu, Annpey Pong, Jianxin Lin, Nilo B Cater, Richard E Pratley
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease - analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin. Diabetes, obesity & metabolism (2022)
Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, Francesco Cosentino, Jie Liu, Annpey Pong, Ira Gantz, Robert Frederich, James P Mancuso, Richard E Pratley
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV. Diabetes, obesity & metabolism 24 (7) (2022)
Francesco Cosentino, Christopher P Cannon, Robert Frederich, David Z I Cherney, Samuel Dagogo-Jack, Richard E Pratley, James P Mancuso, Mario Maldonado, Nilo B Cater, Shuai Wang, Darren K McGuire
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial. Circulation 146 (8) (2022)
Yuliya Lytvyn, Karen Kimura, Nuala Peter, Vesta Lai, Josephine Tse, Leslie Cham, Bruce A Perkins, Nima Soleymanlou, David Z I Cherney
Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition. Circulation 146 (6) (2022)
Lisa Dubrofsky, Jason F Lee, Parisa Hajimirzarahimshirazi, Hongyan Liu, Alanna Weisman, Patrick R Lawler, Michael E Farkouh, Jacob A Udell, David Z I Cherney
A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes. Canadian journal of kidney health and disease 9 (2022)
David Z I Cherney, Francesco Cosentino, Richard E Pratley, Samuel Dagogo-Jack, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Chih-Chin Liu, Christopher P Cannon, null null
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV. Diabetes, obesity & metabolism 24 (6) (2022)
Simke W Waijer, Priya Vart, David Z I Cherney, Glenn M Chertow, Niels Jongs, Anna Maria Langkilde, Johannes F E Mann, Ofri Mosenzon, John Joseph Valentine McMurray, Ellen Burgess, Ricardo Correa-Rotter, Bergur V Stefansson, Robert D Toto, David C Wheeler, Hiddo J Lambers Heerspink
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia 65 (7) (2022)
Taha Sen, Rosalie A Scholtes, Peter J Greasley, David Z I Cherney, Claire C J Dekkers, Marc G Vervloet, Alexander H J Danser, Sean J Barbour, Cecilia Karlsson, Ann Hammarstedt, Qiang Li, Gozewijn D Laverman, Petter Bjornstad, Daniel H van Raalte, Hiddo J Lambers Heerspink
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes, obesity & metabolism 24 (8) (2022)
Patrick R Lawler, Hongyan Liu, Claudia Frankfurter, Leif Erik Lovblom, Yuliya Lytvyn, Dylan Burger, Kevin D Burns, Davor Brinc, David Z I Cherney
Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes. Diabetes care 44 (3) (2021)
David Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, Francesco Cosentino, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Jie Liu, Shuai Wang, Christopher P Cannon, null null
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. Clinical cardiology 44 (8) (2021)
Annemarie B van der Aart-van der Beek, David Z I Cherney, Gozewijn D Laverman, Bergur Stefansson, Daniel H van Raalte, Klaas Hoogenberg, Daniel Reyner, Qiang Li, Gian Luca Di Tanna, Peter J Greasley, Hiddo J Lambers Heerspink
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials. Diabetes, obesity & metabolism 23 (8) (2021)
David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong, Christopher P Cannon, null null
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia 64 (6) (2021)
Vikas S Sridhar, Habib U Rahman, David Z I Cherney
What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors? Diabetes, obesity & metabolism (2021)
Bruce A Perkins, Leif Erik Lovblom, Sebastien O Lanctôt, Krista Lamb, David Z I Cherney
Discoveries from the study of longstanding type 1 diabetes. Diabetologia 64 (6) (2021)
David Z I Cherney, Eleuterio Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, Amy K Carroll, Pablo Lapuerta, Phillip Banks, Rajiv Agarwal
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes, obesity & metabolism 23 (12) (2021)
Marko Škrtić, David Z I Cherney, Vikas S Sridhar, Christopher T M Chan, Abhijat Kitchlu
SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series. Canadian journal of kidney health and disease 8 (2021)
Hongyan Liu, Vikas S Sridhar, Daniel Montemayor, Leif Erik Lovblom, Yuliya Lytvyn, Hongping Ye, Jiwan Kim, Mir Tariq Ali, Daniel Scarr, Patrick R Lawler, Bruce A Perkins, Kumar Sharma, David Z I Cherney
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. Diabetes, obesity & metabolism 23 (11) (2021)
David Z I Cherney, Hiddo J L Heerspink, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Zhi J Xu, Shrita Patel, Anne Hickman, James P Mancuso, Ira Gantz, Steven G Terra
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia 63 (6) (2020)
Adeera Levin, Daniel Sapir, Andrew Steele, David Z I Cherney, Ian C Hellstrom, Matthew B Lanktree, Louise Moist, Rita S Suri
Proceedings From a Canadian Nephrology Forum: Nephrology Is Back. Canadian journal of kidney health and disease 7 (2020)
Lisa Dubrofsky, Anand Srivastava, David Z I Cherney
Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. Canadian journal of kidney health and disease 7 (2020)
Carissa Vinovskis, Lu-Ping Li, Pottumarthi Prasad, Kalie L Tommerdahl, Laura Pyle, Robert G Nelson, Meda E Pavkov, Daniel van Raalte, Marian Rewers, Marlon Pragnell, Farid H Mahmud, David Z I Cherney, Richard J Johnson, Kristen J Nadeau, Petter Bjornstad
Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes. Diabetes 69 (12) (2020)
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J Lambers Heerspink, David Z I Cherney
The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. Diabetes care 42 (10) (2019)
Mehmet Kanbay, Lale A Ertuglu, Baris Afsar, Elif Ozdogan, Zeynep S Kucuksumer, Alberto Ortiz, Adrian Covic, Masanari Kuwabara, David Z I Cherney, Daniel H van Raalte, Dick de Zeeuw
Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. Diabetes, obesity & metabolism 21 (11) (2019)
Maryam Afkarian, Sarit Polsky, Afshin Parsa, Ronnie Aronson, Maria Luiza Caramori, David Z I Cherney, Jill P Crandall, Ian H de Boer, Thomas G Elliott, Andrzej T Galecki, Allison B Goldfine, J Sonya Haw, Irl B Hirsch, Amy B Karger, Ildiko Lingvay, David M Maahs, Janet B McGill, Mark E Molitch, Bruce A Perkins, Pradipta R Ray, Marlon Pragnell, Sylvia E Rosas, Peter Rossing, Peter Senior, Ronald J Sigal, Catherine Spino, Katherine R Tuttle, Guillermo E Umpierrez, Amisha Wallia, Ruth S Weinstock, Chunyi Wu, Michael Mauer, Alessandro Doria, null null
Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. Diabetes care 42 (8) (2019)
Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M B Laffel, David Z I Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George, Jan Marquard, Nima Soleymanlou
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. Diabetes care 42 (9) (2019)
Julie A Lovshin, Julie A Lovshin, David Z I Cherney
Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081. Diabetes care 40 (11) (2018)
Julie A Lovshin, Petter Bjornstad, Leif E Lovblom, Johnny-Wei Bai, Yuliya Lytvyn, Geneviève Boulet, Mohammed A Farooqi, Sam Santiago, Andrej Orszag, Daniel Scarr, Alanna Weisman, Hillary A Keenan, Michael H Brent, Narinder Paul, Vera Bril, Bruce A Perkins, David Z I Cherney
Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes care 41 (12) (2018)
Julio Rosenstock, Jan Marquard, Lori M B Laffel, Dietmar Neubacher, Stefan Kaspers, David Z I Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou, Bruce A Perkins
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes care 41 (12) (2018)
Petter Bjornstad, Lori M B Laffel, William V Tamborlane, Gudrun Simons, Stefan Hantel, Maximilian von Eynatten, Jyothis George, Jan Marquard, David Z I Cherney
Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes. Diabetes care 41 (8) (2018)
Petter Bjornstad, Pattara Wiromrat, Richard J Johnson, Rachel Sippl, David Z I Cherney, Randy Wong, Marian J Rewers, Janet K Snell-Bergeon
Serum Uromodulin Predicts Less Coronary Artery Calcification and Diabetic Kidney Disease Over 12 Years in Adults With Type 1 Diabetes: The CACTI Study. Diabetes care 42 (2) (2018)
Petter Bjornstad, Julie A Lovshin, Yuliya Lytvyn, Genevieve Boulet, Leif E Lovblom, Omar N Alhuzaim, Mohammed A Farooqi, Vesta Lai, Josephine Tse, Leslie Cham, Andrej Orszag, Daniel Scarr, Alanna Weisman, Hillary A Keenan, Michael H Brent, Narinder Paul, Vera Bril, Bruce A Perkins, David Z I Cherney
Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes care 41 (4) (2018)
Julie A Lovshin, Yuliya Lytvyn, Leif E Lovblom, Alexandra Katz, Geneviève Boulet, Petter Bjornstad, Vesta Lai, Leslie Cham, Josephine Tse, Andrej Orszag, Hillary A Keenan, Narinder Paul, Vera Bril, David T Wong, Kylen D McReelis, Michael H Brent, Bruce A Perkins, David Z I Cherney
Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes care 42 (2) (2018)
Alanna Weisman, Leif E Lovblom, Hillary A Keenan, Liane J Tinsley, Stephanie D'Eon, Genevieve Boulet, Mohammed A Farooqi, Julie A Lovshin, Andrej Orszag, Yuliya Lytvyn, Michael H Brent, Narinder Paul, Vera Bril, David Z I Cherney, Bruce A Perkins
Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. Diabetes care 41 (1) (2017)
Yuliya Lytvyn, Ronnie Har, Amy Locke, Vesta Lai, Derek Fong, Andrew Advani, Bruce A Perkins, David Z I Cherney
Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. Diabetes 66 (7) (2017)